Research Analysts Offer Predictions for ZVRA FY2025 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report released on Thursday, March 13th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings of ($0.32) per share for the year, down from their prior forecast of ($0.23). HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics' FY2026 earnings at $0.58 EPS, FY2027 earnings at $1.48 EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $2.51 EPS.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $12.00 million for the quarter, compared to analysts' expectations of $8.93 million.

Other research analysts have also issued reports about the company. Canaccord Genuity Group increased their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, Guggenheim increased their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $22.29.

Remove Ads

Zevra Therapeutics Stock Up 1.4 %

NASDAQ:ZVRA traded up $0.11 during mid-day trading on Monday, hitting $8.06. 193,281 shares of the company's stock traded hands, compared to its average volume of 575,278. The company has a fifty day moving average of $7.91 and a 200 day moving average of $8.17. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a market capitalization of $436.17 million, a P/E ratio of -4.08 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $53,000. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $94,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $94,000. Intech Investment Management LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $95,000. Finally, Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $127,000. Institutional investors and hedge funds own 35.03% of the company's stock.

Insider Activity

In other news, EVP Joshua Schafer sold 10,500 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares in the company, valued at $231,759.96. This trade represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO R. Laduane Clifton sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock worth $674,176 over the last quarter. 2.40% of the stock is currently owned by corporate insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.